title: Helicobacter cinaedi bacteremia resulting from antimicrobial resistance acquired during treatment for X-linked agammaglobulinemia.
abstract: This is the first report of penicillin/cephalosporin-resistant Helicobacter cinaedi arising from prolonged treatment. H. cinaedi, common among immunocompromised patients, caused recurrent bacteremia and cellulitis in a 19-year-old Japanese man with X-linked agammaglobulinemia. The minimal inhibitory concentration of these drugs was raised, which subsequently resulted in clinical failure. Prolonged suboptimal treatment may cause bacterial resistance to β-lactam antibiotics in H. cinaedi. It is possible that this resistance may have contributed to the treatment failure.
authors.affiliation: Division of Infectious Diseases, Tokyo Metropolitan Children's Medical Center, Japan; Department of Pediatrics, Children's Center, Yokohama Rosai Hospital, Japan. Electronic address: meiwajv@hotmail.com.
authors.forename: Meiwa
authors.initials: M
authors.lastname: Toyofuku
authors.affiliation: Department of Microbiology, School of Pharmacy, Aichi Gakuin University, Japan.
authors.forename: Junko
authors.initials: J
authors.lastname: Tomida
authors.affiliation: Department of Microbiology, School of Pharmacy, Aichi Gakuin University, Japan.
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Kawamura
authors.affiliation: Department of Pediatrics, Kawasaki Medical School, Japan.
authors.forename: Ippei
authors.initials: I
authors.lastname: Miyata
authors.affiliation: Division of Hematology/Oncology, Tokyo Metropolitan Children's Medical Center, Japan.
authors.forename: Yuki
authors.initials: Y
authors.lastname: Yuza
authors.affiliation: Division of Infectious Diseases, Tokyo Metropolitan Children's Medical Center, Japan.
authors.forename: Yuho
authors.initials: Y
authors.lastname: Horikoshi
mesh_terms: D000328:Adult; D000361:Agammaglobulinemia / Q000188:drug therapy*; D000658:Amoxicillin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D016470:Bacteremia / Q000188:drug therapy / Q000276:immunology / Q000382:microbiology*; D002481:Cellulitis / Q000188:drug therapy / Q000276:immunology / Q000382:microbiology*; D018550:Cephalosporin Resistance; D002511:Cephalosporins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D040181:Genetic Diseases, X-Linked / Q000188:drug therapy*; D016998:Helicobacter / Q000187:drug effects / Q000302:isolation & purification*; D016481:Helicobacter Infections / Q000188:drug therapy / Q000382:microbiology*; D006801:Humans; D016867:Immunocompromised Host; D007136:Immunoglobulins / Q000009:adverse effects* / Q000627:therapeutic use; D007866:Leg; D008297:Male; D008826:Microbial Sensitivity Tests; D010403:Penicillin Resistance; D017211:Treatment Failure; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D007136:Immunoglobulins; D000658:Amoxicillin
keywords: Antimicrobial resistance; Bacteremia; Cellulitis; Helicobacter cinaedi; X-linked agammaglobulinemia